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1. Introduction 
Liver transplantation (LT) is the replacement of a diseased liver with a healthy liver 
allograft. It has been recognized as the only definitive treatment of end stage liver 
disease. It increases both life expectancy and quality of life for patients, and it can be 
the definitive cure for some acquired and genetic liver diseases. Indications for liver 
transplantation include acute liver failure, hepatic decompensation due to chronic 
liver disease, primary hepatic malignancy and a variety of metabolic disorders. (1)  
In 2012 a total of 6973 livers were transplanted in the European Union (EU), with live 
liver donations making up 3.7% of these. Globally, the percentage of live liver 
donations made up 18.2% of a total number of 23986. In 2013,1562 livers were 
transplanted within the Eurotransplant area, which includes Austria, Belgium, Croatia, 
Germany, Hungary, Luxembourg, the Netherlands and Slovenia. Liver transplants 
had the highest quality adjusted life years (QALYs) gained with 11.5, compared to 
heart and lung transplants, with 6.8 and 5.2 QALYs gained, respectively. (2) The 
survival rates for deceased donor transplantations are approximately 86 and 72 
percent for 1 and 5 years, respectively, and for living donor transplantations the 
survival rates are 90 and 78 percent. (3) 
Because there is a lack of donors and a relative high demand for donor livers, and 
also because invasive testing during patient selection and preoperative screening 
can pose dangers, it is important to identify the patients who will benefit the most 
from the procedure. (1)  
Advanced liver disease affects all other organ system, and it requires a skilled 
anesthesiologist to manage the complications that can arise before and during 
surgery. The surgery is divided into three phases, preanhepatic (stage I), anhepatic 
(stage II) and neo-hepatic (stage III), and the anesthetic management is described 
according to these stages, with each posing different challenges for the 
anesthesiologist. 
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2. Sažetak 
Transplantacija jetre je zamjena bolesne jetre sa zdravim alotransplantatom jetre. 
Prepoznata je kao jedini konačni oblik liječenja terminalne bolesti jetre. 
Transplantacija produljuje očekivano trajanje života te može dovesti do izlječenja kod 
osoba s nasljednim i genetskim bolestima jetre. Indikacije za transplantaciju jetre 
uključuju akutno zatajenje jetre, dekompenzaciju zbog kronične bolesti jetre, 
primarnu malignu bolest jetre te različite metaboličke bolesti.(1) 
U 2012. ukupno su 6973 jetre bile transplantirane unutar Europske unije (EU). Od 
toga broja 3.7% su činili živi donori. U svijetu je postotak živih donora činio 18.2% od 
ukupno 23986 transplantacija. U 2013. 1562 jetre su transplantirane u regijama u 
kojima djeluje Eurotransplant što uključuje Austriju, Belgiju, Hrvatsku, Njemačku, 
Mađarsku, Luksemburg, Nizozemsku i Sloveniju. Transplantati jetre imali su najviše 
kvalitete podešenih godina života – QALY, s 11.5 godina, u usporedbi sa 
transplantacijom srca i pluća, sa 6.8, odnosno 5.2 QALY-ja. (2) Stope preživljavanja 
za transplantacije od kadaveričnih donora su od prilike 86% i 72%, a za one od živih 
donora su 90% i 78%. (3) 
Zbog manjka donora, relativno velike potražnje za doniranim organima te zbog 
invazivnog testiranja tijekom odabira pacijenata i preoperativne obrade, koji mogu 
predstavljati opasnost za pacijenta, od iznimne je važnosti prepoznati pacijenata koji 
će imati najviše koristi od transplantacije. (1) 
Uznapredovala bolest jetra zahvaća sve ostale organske sustave te je potrebno imati 
vještog (iskusnog) anesteziologa koji će se moći nositi s komplikacijama koje se 
mogu razviti prije, tijekom i nakon operacije. 
Operacija se može podijeliti u tri faze; preanhepatična (stadij I), anhepatična (stadij II) 
i neohepatična (stadij III) te je vođenje anestezije opisano u skladu s tim stadijima i 
svaki od njih predstavlja drugačiji izazov za anesteziologa.  
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3. History 
Orthotopic liver transplantation, which is the placement of a liver allograft in its normal 
anatomical position, was first described by Francis Moore who performed trials with 
LT in dogs in 1958. This was followed in 1963 by Thomas Starzl et al, who performed 
the first liver transplantations in humans. (4) The first patient was a 3 year old boy 
with biliary atresia, who died during surgery due to coagulopathy and uncontrolled 
bleeding.  The next four attempts were made in adults, who all survived the surgery, 
but died in the postoperative period from pulmonary embolisms that originated from 
the bypass tubing. (5) 
Initially, the immunosuppressive regimen was the same as used for renal 
transplantation, azathioprine and corticosteroids. The failed attempts in 1963 
represented the beginning of a moratorium which lasted more than 3 years, with a 
return to the laboratory to improve surgical techniques and immunosuppressive 
therapy. In 1967 the trials were resumed. 8 pediatric patients were transplanted, all 
survived surgery, but all but one died within 2.5 years, from rejection due to 
insufficient immunosuppression, or recurrence of the underlying disease. One patient 
who was transplanted in 1970, whose underlying condition was biliary atresia, had a 
remarkable survival and was still alive in 2002. (5) 
In Europe, the first liver transplantation was performed in 1971 on a 17 month old 
child with biliary atresia. He survived the surgery, and developed acute rejection 
which was reversed by steroid therapy. Unfortunately he died from uncontrolled 
bleeding after a liver biopsy 7 weeks postoperatively. (5) 
In 1979, trials were started with cyclosporine A as immunosuppression, which greatly 
increased survival. By 1984, liver transplantation was no longer considered 
experimental, and was approved as a therapy for end stage liver disease. In 1989, 1 
and 5 year survival were reported as 73% and 64%, respectively in 1179 patients. 
From 1990, tacrolimus was used in patients who still suffered rejection with 
cyclosporine. (4)  
Due to the shortage of donor livers, the technique of liver reduction was developed, 
where a large cadaveric donor liver was divided into smaller segments that could be 
transplanted into several recipients. This technique has been criticized and is no 
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longer used as it could favour pediatric patients over adult patients, simply because 
one liver could be used in more pediatric patients than in adults, who need bigger 
grafts. In the 1990s technique of splitting the donor liver was developed, where the 
left lobe or left lateral segment can be transplanted to a pediatric recipient, and the 
right lobe to an adult recipient. (5) 
4. Medical criteria determining the patient’s status on the 
waiting list 
Deciding to list a patient for liver transplantation is based on an objective 
measurement of hepatic dysfunction rather than on the underlying etiology. 
Previously, the Child-Turcotte-Pugh (CTP) score, ABO compatibility and waiting time 
were used to select patients eligible for transplantation. The CTP score has a 
maximum value of 15, and is determined by the presence of hepatic encephalopathy 
and ascites, bilirubin levels, albumin concentration and increase in prothrombin time. 
Patients were divided into 4 categories, depending on their CTP score, need for 
hospitalization and intensive care, and refractory complications of portal hypertension 
or hepatocellular carcinoma. United Network of Organ Sharing (UNOS)  Status 1 was 
reserved for patients with acute fulminant hepatic failure, and priority was given to 
this group. The other categories, UNOS status 2a, 2b and 3, were for patients with 
chronic liver disease, depending on severity.  When deciding which patient should be 
prioritized, waiting time was used as a tie-breaker within a category. (6) Therefore, in 
this system, livers were frequently allocated to patients with less decompensated 
disease, but with longer waiting time. (1) 
Nowadays we use the model for end stage liver disease (MELD), which is a 
mathematical score derived by using three variables, serum bilirubin, international 
normalized ratio (INR) and creatinine, with a maximum score of 40. (7) It is calculated 
according to the following equation: 
MELD Score = 0.957 x Log (creatinine mg/dL) + 0.378 x Loge (bilirubin mg/dL) + 
1.120 x Loge (INR) + 0.643 (8) 
The model was developed in 2000, initially to predict mortality in patients undergoing 
transjugular intra-hepatic shunt (TIPS) procedure. It was adopted by UNOS in 2002, 
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to replace UNOS status 2 to 3, and by Eurotransplant (ET) in 2006 for allocation of 
donor livers. UNOS status 1 was unaffected. (9) A higher MELD score indicates 
severe disease and patients are ranked in descending order. It is only applicable for 
patients with chronic liver disease who are listed for elective transplantation. Patients 
with acute fulminant liver failure are given high urgency (HU) status in ET. (8) 
MELD has been shown to accurately predict 3 month mortality in patients with 
chronic liver disease. (6) After implementation of MELD, the waiting list mortality 
decreased. However, the post-transplant morbidity increased, likely due to an 
increase of transplantation in patients with more decompensated liver disease. (10) 
The advantages of MELD over the CTP score, is that MELD is a continuous scale, 
therefore waiting time is no longer an important factor, and the patients are prioritized 
according to their risk of dying in a defined period of time, rather than when they were 
listed for liver transplantation. This has implications for patients with less access to 
health care, who tend to be listed for transplantations later than patients with more 
access to health care. In addition, the MELD score does not depend on subjective 
variables, such as evaluation of ascites or portosystemic encephalopathy. (6) If two 
or more recipients have the same MELD score, the recipient with the longest waiting 
time will be prioritized. (8)  
For patients under the age of 12, a modified version, the pediatric end-stage liver 
disease (PELD) score is used. It is calculated using total bilirubin, INR, albumin, with 
presence/absence of growth failure, and age above or below 1 year. As opposed to 
MELD, it has no upper limit. (7) 
In 15-20% of patients, the MELD score is of limited usefulness because the score 
cannot accurately predict survival. (Hepatology 2016). MELD exceptions were 
developed to more accurately predict patient mortality. Exceptions include 
hepatocellular carcinoma (HCC), hepatopulmonary syndrome, portopulmonary 
hypertension, familial amyloid polyneuropathy, cholangiocarcinoma, cystic fibrosis, 
metabolic disease, hepatic artery thrombosis and primary hyperoxaluria. These 
patients will be assigned a higher MELD score than their laboratory values suggest, 
and will receive an increase in points every three months. (11) 
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4.1 Indications for liver transplantation 
In 2015 7127 LTs were perfomed in the US, and the etiologies were hepatitis C 
(26.2%), alcoholic liver disease (25.9%), cholestatic disease (8.3%), malignancy 
(7.2%), acute liver failure (1.9%) and others/unknown (30.6%). A reduction in patients 
presenting for transplantation with Hepatitis C infection was reported, and it is no 
longer the most common etiology for transplantation. This is likely due to introduction 
of effective antiviral therapy in 2014. The number of recipients in the category 
others/unknown has increased, likely due to an increase in non-alcoholic fatty liver 
disease. (12)  
In adults the most common indications are cirrhosis, primary biliary cirrhosis and 
primary sclerosing cholangitis. The main indications in the pediatric population are 
primary biliary atresia, followed by metabolic disorders, such as alpha-1 antitrypsin 
deficiency, Wilson’s disease, tyrosinemia and Crigler-Najjar type-1 syndrome, and 
fulminant hepatic failure, cryptogenic cirrhosis, neonatal hepatitis and malignancy. 
(13)  
A list of medical indications for liver transplantation is provided in table 1.  
 
Table 1: Medical indications for liver transplantation.  
Medical indications for liver transplantation 
Viral Hepatitis C 
Hepatitis B 
Autoimmune liver disease  
Alcohol-related liver disease  
Inherited/metabolic liver diseases Hereditary hemochromatosis 
α-1-Antitrypsin deficiency 
Nonalcoholic fatty liver disease 
Tyrosinemia 
Type IV glycogen storage disease 
Neonatal hemochromatosis 
Amyloidosis 
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Hyperoxaluria 
Urea cycle defects 
Amino acid defects 
Cholestatic liver disease Primary biliary cirrhosis 
Primary sclerosing cholangitis 
Biliary atresia 
Alagille syndrome 
Progressive familial intrahepatic 
cholestasis 
Cystic fibrosis 
Bile duct loss 
Malignancy Hepatocellular carcinoma 
Cholangiocarcinoma 
Fibrolamellar carcinoma 
Epithelioid hemangioendothelioma 
Hepatoblastoma 
Metastatic neuroendocrine tumor 
Polycystic liver disease  
Vascular disorder Budd-Chiari syndrome 
Fulminant hepatic failure  
Retransplantation  
from : Fox A, Brown R. Is the Patient a Candidate for Liver Transplantation?. Clinics 
in Liver Disease. 2012;16(2):435-448. 
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4.2 Contraindications for liver transplantation 
Contraindications for LT are divided into absolute and relative and are presented in 
table 2. 
Table 2: Contraindications to liver transplantation.  
Contraindications to liver transplantation 
Absolute contraindications Relative contraindications 
Severe cardiopulmonary disease Advanced age 
Other outstanding malignancy Obesity 
Hepatic malignancy with vascular 
invasion or beyond transplantable 
criterion 
Psychiatric disease 
Extrahepatic malignancy HIV infection 
Active infection Surgical challenges: prior extensive intra-
abdominal surgeries, extensive vascular 
thrombosis 
Active substance abuse  
Poor psychosocial support  
Poor compliance  
 
from Fox A, Brown R. Is the Patient a Candidate for Liver Transplantation?. Clinics in 
Liver Disease. 2012;16(2):435-448. 
 
5. Preoperative evaluation 
Before any surgery it is essential to perform a preoperative evaluation to assess a 
patient’s risk of perioperative morbidity and mortality, and to optimize the patient for 
the procedure. In patients without comorbidities, it is enough to do a thorough history 
and physical examination with focus on risk factors for cardiovascular and respiratory 
diseases. (14) However, ESLD adversely affects all organ systems, and due to the 
shortage of donor livers and the effects of ESLD on perioperative morbidity and 
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mortality, it is important to identify patients who will most benefit from LT. Pre-LT 
evaluation has two main objectives, to assess the risk for perioperative morbidity and 
mortality, and to estimate long term survival. (15) According to the American 
Association for the study of liver diseases (AASLD) typical evaluation of patients 
undergoing LT should include a careful history and physical examination, 
cardiopulmonary assessment, laboratory studies to confirm the etiology and severity 
of liver disease, creatinine clearance, laboratory studies to determine the status of 
hepatitis B and C virus, Ebstein Barr virus, cytomegalovirus, and HIV infection, and 
abdominal imaging to determine hepatic artery and portal vein anatomy and the 
presence of HCC. (16) 
The cardiopulmonary evaluation in patients presenting for LT is complex. Cardiac 
events are common in these patients, occurring in 25-70% of patients in the intra- or 
postoperative period, and it has a significant effect on prognosis. Patients undergoing 
LT should be assessed for common conditions, such as coronary artery disease, 
hyperdynamic circulatory state and cirrhotic cardiomyopathy, as well as obstructive or 
restrictive lung disease, hepatopulmonary syndrome, and pulmonary hypertension. 
(15) (16) 
The prevalence of coronary artery disease (CAD) in LT candidates ranges from 2,5-
27%, and due to the poor physical status of these patients may not experience 
common symptoms of CAD. In the perioperative period there is an increase in 
metabolic and oxygen demands of the myocardium, and coronary blood flow may be 
insufficient if coronary artery occlusion is present. CAD impacts morbidity and 
mortality both during LT and postoperatively. Therefore, it is essential to detect silent 
CAD.  Stress testing should be performed in patients with coronary risk factors, and 
drug stress testing is preferred as these patients given the poor physical status in LT 
candidates. Given a positive stress test, coronary angiography should be performed. 
(15) 
A 12-lead electrocadiography (ECG) should be performed in all LT patients. Cirrhotic 
cardiomyopathy, a common conditions in patients with ESLD, presents with a long 
QTc interval. (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4782417/) It can also be 
detected by echocardiography. Although the prevalence of valvular heart disease is 
13 
 
expected to be low, the severity of valve dysfunction is predictive of perioperative 
complications. (15) 
A careful pulmonary evaluation should be perfomed, even in asymptomatic patients. 
A routine preoperative evaluation of pulmonary function should include a thorough 
history and physical examination, arterial blood gas analysis, chest x-ray, pulmonary 
function tests (PFTs) as spirometry, and a Doppler echocardiography to estimate 
pulmonary artery pressure and exclude increased pulmonary vascular resistance. 
(17) A positive Doppler echocardiography should be followed up by right heart 
catheterization for some patients. (16) 
Patients with chronic kidney disease have poor survival after LT, whereas patients 
with hepatopulmonary syndrome drastically improve after transplantation. Patients 
should undergo a thorough evaluation of renal function prior to transplantation, and 
certain patients with chronic kidney disease may be considered for a combined liver-
kidney transplantation. (16) 
Osteoporosis is a common finding in ESDL, particularly in postmenopausal women 
and patients with cholestatic disorders such as primary biliary cholangitis (PBC) and 
primary sclerosing cholangitis, therefore all patients should screened for osteoporosis 
due to the risk of pathological fractures in the postoperative period. (16) 
Because of the immunosuppressive regimen that is necessary to facilitate 
transplantation, patients with a history of extrahepatic malignancies are at an 
increased risk of recurrence, and should therefore be evalutated by an oncologist 
prior to LT. (16) 
It is good to include the anesthesiologist in preoperative evaluation early enough  to 
enable optimizing the patient and tailoring a good anesthesia plan for every patient. 
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Figure 1: Preoperative cardiovascular assessment. (18) 
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6.    Diseases related to chronic liver disease 
6.1 Portal hypertension 
Portal hypertension represents a common complication of chronic liver disease, and 
it is the main cause of hospitalization, LT and mortality among patients with cirrhosis. 
The most common cause of portal hypertension in the western world is cirrhosis, 
however around 10% of cases are due to non-cirrhotic causes, such as 
schistosomiasis and idiopathic portal hypertension. Portal hypertension has two 
components, a structural and a dynamic component. The structural changes, caused 
by fibrotic changes in the liver architecture, accounts for the biggest increase in 
pressure. The dynamic component accounts for around 30% of the increased portal 
pressure, and is caused by increased local production of vasoconstrictors and 
decreased availability of vasodilators. (19) As the resistance increases, development 
of collateral vessels and a hyperdynamic circulatory state further aggravates portal 
hypertension. (20) 
Portal hypertension is defined by a hepatic venous pressure gradient (HVPG) of 
more than 10 mmHg, (19) and is predictive of development of complications. (21) A 
normal HVPG is below 5 mmHg, and values between 5 and 9 represent subclinical 
portal hypertension. (19) HPVG is the difference between the wedged and the free 
hepatic pressures, and represents the pressure gradient between the hepatic vein 
and the intra-abdominal portion of the inferior vena cava. (21) 
Clinical manifestations of portal hypertension include development of collateral 
circulation, such as esophageal varices and abdominal wall collateral vessels, portal 
hypertensive gastropathy, spontaneous bacterial peritonitis, ascites, hepatic 
hydrothorax, hepatopulmonary syndrome, portopulmonary hypertension, cirrhotic 
cardiomyopathy and hepatic encephalopathy. (19) 
At levels above 10 mmHg, the patient is at increased risk of developing esopageal 
varices and HCC. Above 12 mmHg, the risk of variceal bleeding increases, and at 16 
mmHg the risk of mortality is increased. With levels above 30 mmHg, there is risk of 
spontaneous bacterial peritonitis. (19)  
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6.2 Central nervous system 
Patients with cirrhosis frequently have neurologic signs and symptoms, and the most 
common neurologic manifestion is hepatic encephalopathy. Hepatic encephalopathy 
is a spectrum of reversible neuropsychiatric abnormalities ranging from mildly altered 
mental status to coma and death. Subclinical hepatic encephalopathy is detected 
only by psychomotor testing, and is usually characterized by subtle clinical 
symptoms. (22)  The severity of overt hepatic encephalopathy is graded from I to IV 
based on clinical symptoms, where grade I represents changes in behavior, mild 
confusion, slurred speech and disordered sleep. Grade II is characterized by lethargy 
and moderate confusion. Grade III is marked confusion, stupor, incoherent speech 
and asleep but arousable, and patients with grade IV hepatic encephalopathy are 
comatose and unresponsive to pain. The mechanism is not clear, but current theories 
suggest a combination of gamma-amino butyric acid (GABA) potentiation by 
ammonia and chronic low grade glial edema may be responsible for the symptoms. 
(22) 
Patients who develop encephalopathy due to acute liver failure have a poor 
prognosis, with rapid progression of symptoms and mortality from 70% to 80%. 
However, in clinical practice, the more common form is chronic encephalopathy 
associated with end stage liver disease. For these patients the 1 year survival after 
the first episode of encephalopathy is 40%, and at 3 years the survival is 15%. These 
patients usually have slower progression and milder symptoms, and it is typically 
triggered by precipitating causes such as gastrointenstinal bleeding, infection, 
electrolyte disturbances or constipation, among others. Treatment is aimed at 
removal of the precipitating factors, and for patients with chronic encephalopathy, 
protein restriction can be effective. (22)  
6.3 Cardiovascular system 
Liver cirrhosis is associated with a spectrum of cardiovascular abnormalities, 
including hyperdynamic circulations and cirrhotic cardiomyopathy. (23) The 
mechanism of hyperdynamic circulation in cirrhosis is peripheral and splanchnic 
vasodilation, due to an increased production and activity of vasodilators such as nitric 
oxide, carbon monoxide and endogenous cannabinoids, as well as decreased 
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reactivity to vasoconstrictors. Early on, the decreased vascular resistance is 
compensated for by an increase in cardiac output. However, later on, an increase in 
cardiac output can no longer compensate for the decreased systemic vascular 
resistance. This leads to underfilling of the arterial circulation, and thereby decreased 
effective blood. To maintain effective arterial blood volume and arterial pressure, 
several vasoconstrictor systems are activated, such as the renin-angiotensin-
aldosterone system, sympathetic nervous system and antidiuretic hormone. 
Activation of these systems causes sodium and water retention, which is the main 
mechanism behind the development of ascites. (24)  
Liver dysfunction not only adversely affects the circulation, but also cardiac 
contractility. The main clinical features of cirrhotic cardiomyopathy  aresystolic and 
diastolic dysfunction and electrophysiologic abnormalities (25),  in the absence of 
other causes of cardiac dysfunction. Systolic dysfunction is mostly latent and is 
unmasked by physical or pharmacologic stress.  Systolic dysfunction in cirrhotic 
patients is caused by alterations in beta-adrenergic signaling pathways, increased 
cholesterol content in the myocadial cell membranes which may alter ion channel 
functions, enhanced endocannabinoid signaling which has a negative inotropic effect, 
and NO overproduction, which has a toxic effect on the myocardium. (26) 
Myocardial hypertrophy and fibrosis due to activation of the RAAS as well as 
subendothelial edema and increased interstital collagen deposition leads to diastolic 
dysfunction. This is characterized by decreased ventricular relaxation and inadequate 
ventricular filling, increased atrial pressure and prolonged isovolumetric relaxation. 
(26) It can be seen on Doppler echocardiography as a decreased E/A ration. (24)  
The electrophysiological abnormalities in cirrhotic cardiomyopathy comprise of 
chronotropic incompetence, electromechanic uncoupling and prolonged QT interval. 
(26) Chronotropic incompetence is an inability to increase the heart rate with 
increased demands, which lead to exercise intolerance (27) and electromechanical 
uncoupling is an asynchrony between the electrical and mechanical activity of the 
heart. QT prolongation is present in around 60% of patients with cirrhosis. These 
phenomena are correlated to the severity of liver disease. (26)  
18 
 
6.4 Renal system 
Renal failure is a common complication of cirrhosis. Renal failure in these patients is 
related to the circulatory changes mentioned previously. Prolonged activation of 
vasoconstrictor systems brought on by splanchnic vasodilation and low systemic 
vascular resistance leads to severe renal vasoconstriction which may progress to a 
severe reduction in GFR and renal insufficiency, known as hepatorenal syndrome  
(HRS). (24) HRS exists as two types. Type 1 is characterized by a rapid onset with 
doubling of serum creatinine concentration within two weeks. It is associated with 
severe multiorgan dysfunction, and it carries a poor prognosis with a very low short 
term survival rate. Type 2 has a slower and more progressive onset. (28)  These 
patients have diuretic resistant ascites and slightly longer survival.(29) Activation of 
vasoconstrictor systems lead to retention of sodium and water, therefore HRS is 
rarely present in the absence of ascites. (28) 
HRS can be precipitated by factors that further impair renal circulation, such as 
hypovolemia due to gastrointestinal bleeding, large volume paracentesis without 
adequate plasma expansion and bacterial infections. A clear relation has been 
established between spontaneous bacterial peritonitis and development of HRS. (30) 
HRS is a diagnosis of exclusion. It can only be diagnosed in the setting of cirrhosis 
with ascites, in the absence of shock with serum creatinine >113mml/L, no 
improvement of kidney function 2 days after volume expansion and diuretic 
withdrawal, no current or recent treatment with nephrotoxic drugs and in the absence 
of parenchymal kidney disease. (31) Spontaneous recovery is rare, and the only 
effective treatment for HRS is LT. (30) 
The main differential diagnosis is acute tubular necrosis (ATN). ATN should be 
suspected if renal failure develops immediately after administration of nephrotoxic 
drugs, or in the setting of hypovolemic or septic shock. (30) 
6.5 Electrolytes 
Hyponatremia frequently develops in patients with advanced cirrhosis. Activation of 
vasoconstrictor systems causes retention of sodium and water as a compensatory 
mechanism for the low effective circulatory volume. With disease progression, the 
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kidneys are unable to eliminate solute free water. This leads to non-osmotic release 
of ADH, leading to plasma dilution, further aggravating the hyponatremia. (32) 
Currently, treatment is limited to conventional therapies like sodium restriction. 
Althought vasopressin antagonists are available, their role in treatment of patients 
with liver failure is questionable. (33) Hyponatremia correlates with the severity of 
liver disease, serves as a prognostic factor for patients with liver failure,* and is 
included in calculation of the MELD score. 
Hypokalemia can be caused by various reasons such as use of diuretics, 
hyperaldoseronism  due to activation of RAAS, or secondary to hypomagnesemia in 
alcoholic liver disease. (34) 
6.6 Pulmonary system 
Portopulmonary hypertension (POPH) is a form of pulmonary artery hypertension 
(PAH) which is associated with portal hypertension. The prevalence in patients 
undergoing LT is estimated to be 8,5%, as opposed to 2-5% in the general 
population with portal hypertension. The main clinical symptom of POPH is dyspnea 
on exertion, and other symptoms include fatigue, generalized weakness, ligh-
headedness and orthopnea. (35) It is not related to the etiology or severity of liver 
disease, but female sex and presence of autoimmune disease are risk factors for 
development of POPH. (36) 
Patients with POPH present with mean pulmonary artery pressure (mPAP) >25 
mmHg at rest, mean pulmonary capillary wedge pressure (mPCWP) <15 mmHg and 
pulmonary vascular resistance (PVR) >240 /dyne/sec/cm-5 in association with clinical 
portal hypertension with or without significant chronic liver disease. Diagnosis is 
suggested by transesophageal echocardiography (TEE), and confirmed with right 
heart catheterization. Every patient undergoing LT should be screened for POPH with 
TEE. 
The survival of untreated POPH is very poor, with 54% mortality within a year of 
diagnosis, and 5 year survival as low as 14%. In some patients with successful LT 
there can be resolution of POPH with time, (35) however in other patients it persists 
or worsen. (36) 
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Hepatopulmonary syndrome (HPS) is defined by intrapulmonary vascular dilatation 
(IVPD) and hypoxemia in combination chronic liver disease or portal hypertension. 
IVPD can cause a right to left shunt resulting in hypoxemia. (36) The most prominent 
symptom is dyspnea at exertion or at rest. Patients may experience platypnea-
orthodeoxia syndrome, with worsening dyspnea when moving from recumbent to 
upright position due to worsening of right-to-left shunting and thereby a decrease in 
oxygenation. (37) 
The diagnostic criteria for HPS are chronic liver disease with alveolar-arterial oxygen 
pressure gradient (aDO2) ≥ 15 mmHg, or ≥ 20 mmHg, or or ≥ to the age-adjusted 
value, as well as intrapulmonary vascular dilatation at contrast-enhanced 
transesophageal echocardiography(CT-TEE) or Technetium macroaggregated 
albumin lung perfusion scan (99m-TcMAA). IVPD is found in 40-60% of patients with 
liver disease, but only 15-30% have hypoxemia and therefore meet the diagnostic 
criteria for HPS. Patients diagnosed with HPS qualify for MELD exception points. 
Medical treatment for HPS is disappointing, and the definitive treatment for HPS is 
LT. HPS increases perioperative mortality, but 5 year survival is similar in patients 
with and without HPS. (36) 
6.7 Coagulation 
The liver is essential in coagulation, as it is the site of synthesis for procoagulant 
factors, anticoagulant factors, and fibrinolytic proteins. (38) Chronic liver disease is 
characterized by a decrease in most procoagulant factors, with the exception of von 
Willebrand factor and factor VIII. It was previously believed that patients with liver 
failure were „autoanticoagulated“, but newer research has shown that there is also a 
reduction in naturally occurring anticoagulants such as protein C and antithrombin, 
and therefore a paralell reduction in both procoagulant and anticoagulant factors. 
(39)  
All stages in hemostasis may be abnormal, including primary hemostasis, 
coagulation and fibrinolysis. INR is included in calculation of the MELD score, and it 
is linked to the severity and prognosis of liver disease, it is not a good marker for the 
risk of bleeding in these patients, because it does not accurately reflect the changes 
in both the procoagulant and anticoagulant systems. Acute events, such as infection, 
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variceal bleeding and uremia may lead to changes in hemostasis and predispose to 
bleeding. (40)  
This imbalance between pro- and anticoagulants may explain why patients with liver 
disease, despite a bleeding diathesis, are not protected from events such as 
peripheral-vein thrombosis, portal vein thrombosis, atherothrombosis and 
progression of liver fibrosis. (39) 
7. Intraoperative anesthetic management 
There are three distinct stages in in liver transplant surgery which the anesthetic 
team need to be aware of. The stages are each defined by a surgical feature, are 
characterized by specific complications and require different anesthetic 
considerations. These stages are the preanhepatic or dissection stage, the anhepatic 
stage, and the neohepatic or reperfusion stage. (29)  
7.1 Monitoring 
LT causes major fluid shifts, electrolyte disturbances, hemodynamic instability and 
metabolic derangements. Cardiac events are the leading cause of non-graft related 
death, therefore emphasis is placed on hemodynamic monitoring. The type of 
monitoring differs according to the preoperative status of the patients, as well as 
between transplantation centers. Standard monitoring includes ECG, peripheral 
oxygen saturation (SpO2), end tidal CO2, central venous pressure (CVP) and arterial 
blood pressure (ABP). (41) 
As previously mentioned, ESLD is characterized by high cardiac output (CO), 
decreased systemic vascular resistance, and depletion of intravascular volume. In 
addition, during the different stages of LT there are hemodynamic changes that need 
to be recognized and managed. (42) Routine monitoring includes ECG, pulse 
oximetry, capnograph and temperature monitoring. Direct arterial blood pressure, 
central venous and pulmonary artery pressure monitoring should also be in place. 
(13)  For invasive arterial artery pressure, both radial and femoral artery cannulation 
can be used, but the femoral artery is sometime problematic during clamping of the 
aorta. Until recently, pulmonary artery catheter (PAC) was used to monitor cardiac 
filling pressures and guide fluid therapy, but these filling pressures have little positive 
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predicting value in predicting hemodynamic instability. Nowadays CO can be 
measured in selected cases through the PAC using intermittent thermodilution. 
Continuous monitoring of CO is also possible using a heating coil within the PAC. 
This eliminates the need for bolus injections and provides an average CO reading 
over time, as opposed to intermittent readings. Due to the risk of arrhythmias, and the 
inaccuracy of readings if the PAC is placed incorrectly, its use is declining, and is 
now reserved for patients with suspicion of PPH. (43) Additionally, during the 
reperfusion stage, return of cooled blood to the systemic circulation as well as 
infusion of large amounts of fluids may cause inaccurate estimation of CO. (44) 
For the most of the patients less invasive hemodynamic monitoring devices are used. 
Devices that provide a continuous estimate of stroke volume (SV) and CO through 
analysis of the shape of the arterial pulse wave from a peripheral arterial catheter are 
commercially available, and can be used to guide fluid and inotrope therapy.   
TEE provides direct visualization of the function and volume status of the heart, and 
in hemodynamic instability, and can be used to immediately diagnose air or 
thromboembolism, as well as measurement of CO. However, it’s use in LT is limited 
due to the high prevalence of esophageal varices in LT candidates. (43) While grade 
4 esophageal varices is a true contraindication, TEE has been safely performed in 
grade I and II varices. (44) 
Traditionally, coagulation has been monitored using conventional coagulation tests 
(CCTs), such as prothrombin time (PT), activated partial thromboplastin time (APTT), 
platelet count and plasma fibrinogen leves. Even with all of these together, it may not 
provide a complete picture of the coagulation status, and therefore anesthesiologists 
use a combination of CTTs with point of care (POC) devices such as 
thrombelastography or rotation thrombelastometry. These tests measure and 
graphically display changes in viscoelasticity of the blood. They are repeated 
frequently during the course of LT and are used to guide blood product replacement. 
(44) 
Acute fulminant hepatic failure (AFHF) increases the risk for increased ICP, and in 
addition, ICP tends to vary significantly during the course of LT. ICP should be 
monitored, however, due to the coagulopathy associated with AFHF, traditional 
invasive ICP monitoring is associated with a risk of intracranial hemorrhage. Newer 
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noninvasive methods of ICP monitoring are becoming increasingly popular, such as 
Transcranial Doppler (TCD), which measures the blood flow velocity in the middle 
cerebral artery (MCA), and Optic Nerve Sheath Diameter (ONSD), which measures 
changes in the diameter of the optic nerve sheath. These techniques are currently 
not accurate enough to replace traditional ICP monitoring in high risk patients, 
however they are able to distinguish between normal and increased ICP. (43) 
As the liver plays a central role in glucose metabolism, and glucose control tends to 
worsen during LT, frequent plasma glucose monitoring is important during 
anesthesia.. Dyselectrolytemias and acid-base disturbances are frequent in liver 
disease, and should also be monitored and corrected.  Continuous temperature 
monitoring and maintenance of normothermia is important, as hypothermia has 
negative effects on wound healing and coagulation. (44) 
7.2 Induction of anesthesia 
Benzodiazepine premedication appears to be safe, although it should be avoided in 
patients with hepatic encephalopathy. (45) A routine rapid sequence induction with 
cricoid pressure should be performed in order to prevent aspiration. Following 
preoxygenation, induction can be performed using intravenous anesthetic drug. (13) 
Anesthesia is maintained using a volatile agent, such as isoflurane, desflurane or 
sevoflurane. (46)  Another suggested technique is propofol and remifentanil, followed 
by maintenance with desflurane inhalation and remifentanil infusion. (47) Midazolam 
is also useful due to its amnestic properties and small effects on hemodynamics. (13) 
Nitrous oxide should be avoided because of its cardiodepressive effects, and 
tendency for bubble formation. The main objective in induction is to maintain 
cardiovascular stability. (45) Liver failure is frequently associated with renal failure 
and hypokalemia, therefore use of succinylcholine should be avoided. Cis-atracurium 
and atracurium are preferred neuromuscular blocking drugs because of their organ 
independent elimination. However, other neuromuscular blocking drugs, such as 
vecuronium, pancuronium and rocuronium can be used safely. Caution should be 
used with these drugs as they rely on hepatic metabolism. (13) (46) 
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7.3 Preanhepatic stage 
The preanhepatic stage begins with surgical incision and ends with cross clamping of 
the portal vein and the suprahepatic and infrahepatic inferior vena cava (IVC). (48) 
During this stage, the liver is mobilized and dissected. Drainage of massive amounts 
of ascitic fluid, as well as blood loss may lead to hemodynamic instability. (13) The 
risk of bleeding is higher in patients with severe portal hypertension with abundant 
portosystemic shunting in the abdominal wall. The greatest concern at this stage is 
surgical bleeding, and the main goal is to maintain volume status. (29) Hypovolemia 
should be treated withcristaloids, colloids and blood derivates. (48) Fluid 
rescuscitation results in a decreased concentration of coagulation factors, therefore 
packed red cells and fresh frozen plasma should be prepared. Monitoring of 
coagulation parameters differs between centers, but most centers monitor INR, PTT, 
fibrinogen and platelet count, with some centers also using thromboelastography and 
activated clotting time. (13)  In order to prevent blood loss, CVP can be maintained at 
a low level (5 cm H2O). This has been shown to decrease bleeding by 80%, although 
this practice is controversial. (49) In patients with severe portal hypertension, 
octreotide infusion may be used to decrease portal pressure. (29)  Preoperative 
autologous blood donation, erythropoietin administration, intraoperative hemodilution, 
blood salvage and maintenance of normothermia in order to prevent worsening of 
coagulopathy are other techniques used to minimize blood loss. Blood transfusions 
are associated with complications and worse outcomes and therefore its use should 
be kept to a minimum. In case of sudden decrease in expired CO2 in the prescence 
of hemodynamic instability, an air embolism from manipulation of the vena cava 
should be suspected. (13) During the first and second stage of LT surgery, 
aggressive management of potassium levels should be initiated in anticipation of 
hyperkalemia during the reperfusion stage. Methods include insulin and glucose, 
treatment of metabolic acidosis with bicarbonate and maintenance of diuresis. (29) 
7.4 Anhepatic stage 
The anhepatic stage begins with occlusion of vascular inflow to the liver and ends 
with reperfusion. (48)  At this stage the liver is removed, and whatever function 
remained in the dysfunctional liver is lost, which leads to striking changes in the 
patient's physiology. (29)  Clamping the IVC and portal vein and dividing hepatic 
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vascular leads to a loss of venous return. This in turn is a risk for cardiovascular 
collapse with hypotension and decreased CO. An increase in venous pressure 
distally increases the risk for bleeding, edema, renal hypoperfusion and intenstinal 
ischemia. In order to maintain hemodynamic stability and renal perfusion, lessen 
splanchnic congestion and delay development of metabolic acidosis, veno-venous 
bypass (VVB) can be used. (13) VVB involves exctracorporeal circulation of blood 
from the peripheral veins to the central venous circulation. (50)  In the piggyback 
technique, with preservation of flow through the IVC, VVB may not be necessary. 
(13) Hypotension should be treated with vasopressors rather than large amounts 
fluids in order to avoid fluid overload. (29) Complications of VVB include air 
embolism, thromboembolism and inadertent decannulation. (48)  During the 
anhepatic phase, no hepatic clotting factors are produced, leading to worsening 
coagulopathy. Thrombocytopenia can develop or worsen due to massive blood 
transfusions and platelet consumption, (45) and in this stage fibrinolysis may occur 
due to unopposed action of tissue plasminogen activator (tPA). (48) Coagulopathy 
should not be aggressively corrected as this is a temporary phenomenon and will 
quickly stabilize after reperfusion. (29) Absence of lactate and citrate metabolism in 
the liver results in worsening acidosis. Due to citrate accumulation, hypocalcemia 
may develop, and should be treated with I.V. calcium infusion to prevent worsening of 
coagulopathy and cardiac depression. (45) During this phase immunosuppressive 
therapy (corticosteroids) is started. 
7.5 Neo-hepatic stage 
The neo-hepatic stage begins with reperfusion of the new liver through the portal vein 
and ends at completion of the procedure. (48, 29) This stage is further subdivided 
into 5 minutes after reperfusion, and the rest of the procedure, as the first 5 minutes 
are the most critical in terms of hemodynamic stability. During reperfusion, 
sequestrated blood in the graft, as well as blood from the lower body if VVB has not 
been used, return to systemic circulation. (29) Reperfusion is associated with abrupt 
increase in potassium and hydrogen ion concentrations, increased preload, as well 
as a decrease in systemic vascular resistance and blood pressure. After reperfusion 
the graft avidly takes up potassium, and some patients require potassium 
supplementation. (45)  Postreperfusion syndrome is defined as a minimum of 30% 
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decrease in mean systemic blood pressure for more than 1 minute during the first 5 
minutes after reperfusion. (13) This is thought to be caused by cytokines, vasoactive 
substances released by the liver and complement. (45) Hypotension should be 
treated with vasopressors and inotropes. (13) On reperfusion there is a return of 
hyperkalemic, cold, acidotic fluid to the systemic circulation.(45) Calcium chloride and 
sodium bicarbonate are the drugs of choice for treatment of hyperkalemia in order to 
prevent arrythmias.(48) Even without treatment, potassium levels fall within minutes 
of reperfusion, but any EKG changes should be treated promptly. (13) Hypothermia is 
a marker for the presence of graft flow into the systemic circulation. (48) Coagulation 
disorders should be corrected at this stage, however using blood products may result 
in volume overload and a paradoxical increase in blood requirements. Signs of a 
functional liver graft include decreased calcium requirements, improvement in 
acidosis, increased urine output, increased core temperature and biliary output from 
the graft. (13) 
8. Postoperative complications 
Postoperatively transplanted patients are admitted to intensive care unit.  
The main goal is to ensure good perfusion of the graft.  
Early extubation is desirable in some patients. In addition to an increased risk of 
ventilator-associated pneumonia, positive pressure ventilation increases intrathoracic 
pressure, which reduces venous return and may cause venous congestion in the 
graft. (51) Spontaneous ventilation reduces intrapleural pressures, improves venous 
return and hepatic blood flow. Risk factors for prolonged mechanical ventilation 
include severe hepatic encephalopathy and obesity (body mass index >34). Patients 
with primary graft dysfunction, renal failure, cardiovascular failure, neurological 
impairment, who received more than 12 units of blood and have pulmonary edema 
cannot tolerate early extubation, and must be kept on mechanical ventilation at least 
3 hours postoperatively. In case of mechanical ventilation prior to surgery, use of 
more than 15 units of blood, acute liver failure, retransplantation or severe 
preservation injury to the graft, the patient needs to be kept on mechanical ventilation 
for at least 24 hours postoperatively. (13) Difficult weaning from mechanical 
ventilation can be caused by massive transfusion, pleural effusions, inadequate 
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clearing of bronchial secretions, pneumonia and adverse effects of 
immunosuppressive therapy. If prolonged mechanical ventilation is required, 
ventilatory strategies that minimize insults to both the lung and the liver should be 
used. Rapid extubation followed by non-invasive ventilation should be considered. 
(51)  
Patients with cirrhosis tend to have impaired cardiac contractility, and in the 
postoperative period, acidosis, electrolyte disturbances and hypothermia may worsen 
cardiac contractility, leading to circulatory instability. Hypovolemia and pulmonary 
edema may impair gas exchange, leading to insufficient perfusion of the graft. 
Additionally, rapid improvement of pre-existing vasodilatation may cause excessive 
strain on the heart. Cardiac monitoring needs to be in place in the postoperative 
period in order to optimize cardiac output and organ perfusion, and to manage fluid 
and therapy and pharmacologic interventions. After stabilization of postoperative 
hemodynamics, it is important to promote return of sequestrated fluid in the 
peripheral circulation in order to prevent pulmonary edema and congestion in the 
graft. Lowering right ventricular volume and pressure would create pressure gradient 
between the portal and central circulation that draws blood through the liver. (51) 
Primary graft dysfunction (PGD) consists of initial poor function (IPF) and primary 
non-function (PNF). IPF is reversible in most cases, but once it progresses to PNF it 
will ultimately progress to graft loss and retransplantation. IPF and PNF represent 
sequential stages of the same syndrome and therefore signs and symptoms overlap. 
There are no universal definitions for IPF, it can be assessed by alanine 
aminotransferase (ALT), aspartate aminotransferase (AST) and prothrombin time. A 
definition that is widely used is an AST of more than 2000 IU/L, indicating hepatic 
injury, a prothrombin time more than 16 seconds, indicating reduced synthetic ability, 
and ammonia above 50 µmol/L between 2 and 7 days postoperatively. In PNF, a 
progressive rise in AST and ALT is detected in the first 24-48 hours after LT, and is 
characterized by hepatic encephalopathy, uncorrectable coagulopathy, 
hypoglycaemia, hyperkalemia, metabolic acidosis, oliguric renal failure, decreased 
bile production and increased serum bilirubin. This condition requires urgent 
retransplantation. If patients who received massive blood transfusions during surgery 
develop metabolic acidosis followed by alkalosis, this is an indication of good graft 
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function, as transformation of sodium citrate present in transfused blood to sodium 
bicarbonate is dependent on good hepatocyte function. (52) 
Poor graft function, as well as imperfect hemostasis, hypersplenism, hypocalcemia, 
dilutional coagulopathy and thrombocytopenia may cause bleeding in the 
postoperative period. Monitoring by thrombelastography may become necessary, but 
overcorrection of coagulopathy should be avoided due to the risk of hepatic artery or 
portal vein thrombosis. (51) Hepatic artery thrombosis requires urgent 
retransplantation. 
Renal dysfunction is a common complication after LT, with a incidence between 12-
95%, and out of these, 30% are due to acute kidney injury (AKI).  The most common 
cause for AKI post LT is acute tubular necrosis (ATN). Renal dysfunction can also be 
due to pre-existing AKI, pre-existing chronic kidney disease (CKD) or CKD that 
develops as a complication of LT.  (53) 
Because of the necessity of immunosuppression infective complications are the 
leading cause of morbidity and mortality after LT. More than half of LT patients have 
at least one infectious complication and half of post LT deaths are due to infections. 
(54) Potential entry of bacteria from the GI tract during surgery, exposure to 
pathogens during hospitalization, indwelling urinary and vascular catheters and 
prolonged mechanical ventilation predispose LT patients to infection within the first 
month postoperatively. The risk of infection is reduced by prophylactic antibiotics, and 
although there is no consensus on antibacterial prophylaxis, a third-generation 
cephalosporin is preferred. Signs and symptoms include fever, leucocytosis, 
erythema, purulence, drainage and wound dehiscence. (55) Other sources of 
infection, include the donor organ and transfused blood products, especially viral 
infections, and reactivation of previous infections. (53) Herpes simplex virus 
reactivation is common in the immediate postoperative period, but the incidence is 
decreased by prophylactic acyclovir or ganciclovir. (55) In the intermediate period 
after LT, from the second to sixth month, infections are most commonly of viral origin, 
followed by fungal infections. Six months after LT, recipients have the same 
frequency of bacterial infections as the general population. (53)  
29 
 
Long term complication of LT include chronic rejection, renal failure, arterial 
hypertension, diabetes mellitus, dyslipidemia, obesity, skeletal complications such as 
osteopenia, neurologic complications and de novo malignancies. (53) 
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